If you have been reading about Stenabolic and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
=== Biomimetic mineralization === Biomolecules can be incorporated during the MOF crystallization process. Biomolecules including proteins, DNA, and antibodies could be encapsulated within ZIF-8. Enzymes encapsulated in this way were stable and active even after being exposed to harsh conditions (e.g. aggressive solvents and high temperature). ZIF-8, MIL-88A, HKUST-1, and several luminescent MOFs containing lanthanide metals were used for the biomimetic mineralization process. In addition, individual living cells were encapsulated within MOF shells via single-cell nanoencapsulation (SCNE).
In the second case, a biosynthetic pathway needs to be engineered, for example, an E. coli strain that biosynthesizes a novel amino acid (p-aminophenylalanine) from basic carbon sources and includes it in its genetic code. Another example is the production of phosphoserine, a natural metabolite, which required alteration of its pathway flux to increase its production.
=== 1975 leadership election === Heseltine had lost faith in Heath over the second miners' strike and over Heath's personal abrasiveness (Heath had apparently once told him to his face that he was too openly ambitious); his patron Peter Walker had also come to have similar doubts about Heath. Ten days before the October 1974 election, at which Heseltine bucked the national swing by increasing his majority at Henley, he urged Heath to consider his position by the end of the year. It is unclear how Heseltine voted in the first ballot of the 1975 Conservative leadership election, in which the challenger Margaret Thatcher defeated Heath. Norman Tebbit stated that he and John Nott persuaded him to vote for Thatcher so as to open up the way for his preferred candidate Willie Whitelaw to stand on the second ballot. Another (anonymous) close friend later told Michael Crick that Heseltine voted for Thatcher. The Thatcher team had him down as an abstainer, while he refused at the time to reveal how he voted. In his memoirs Heseltine wrote that he abstained in the first ballot, but that he would have voted for Whitelaw in the first ballot had he stood against Heath. Whitelaw admired his drive and energy but looked down on him as "new Money" and is said to have commented that Heseltine was "the sort of man who combs his hair in public". Heseltine toyed with standing himself for the second ballot (in Crick's view his vote would very likely have been derisory), but voted for Whitelaw.
Sources: en.wikipedia.org
===== ADP receptor inhibitors ===== Also known as P2Y12 receptor antagonists, they work by reversibly interacting with the P2Y12 receptor to inhibit the adenosine diphosphate (ADP) receptors on platelets, thus preventing the linkage of platelets by fibrinogen. ADP-induced platelet aggregation and activation are hence hindered. Examples include clopidogrel, prasugrel and ticagrelor. Clopidogrel has a common drug interaction with CYP2C19 inhibitors, particularly omeprazole and esomeprazole which are indicated for treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD). As the activation of clopidogrel requires an enzyme called CYP2C19, its inhibitors should be avoided.
The king remained king in Ireland; Britain retained the so-called strategic Treaty Ports on Ireland's south and north-west coasts which were to remain occupied by the Royal Navy; Prior to the passage of the Statute of Westminster, the UK government continued to have a role in Irish governance. Officially the representative of the king, the Governor-General also received instructions from the British Government on his use of the Royal Assent, namely a Bill passed by the Dáil and Seanad could be Granted Assent (signed into law), Withheld (not signed, pending later approval) or Denied (vetoed). The letters patent to the first Governor-General, Tim Healy, explicitly named Bills that were to be rejected if passed by the Dáil and Seanad, such as any attempt to abolish the Oath. No such Bills were ever introduced.
A vent site in the Cayman Trough named Beebe, which is the world's deepest known hydrothermal site at ~5,000 m (16,000 ft) below sea level, has shown sustained supercritical venting at 401 °C (754 °F) and 2.3 wt% NaCl. Although supercritical conditions have been observed at several sites, it is not yet known what significance, if any, supercritical venting has in terms of hydrothermal circulation, mineral deposit formation, geochemical fluxes or biological activity. The initial stages of a vent chimney begin with the deposition of the mineral anhydrite. Sulfides of copper, iron, and zinc then precipitate in the chimney gaps, making it less porous over the course of time. Vent growths on the order of 30 cm (1 ft) per day have been recorded. An April 2007 exploration of the deep-sea vents off the coast of Fiji found those vents to be a significant source of dissolved iron (see iron cycle).
=== Structure === GsMTx-4 has a polypeptide chain of 35 amino acids with the sequence GCLEF-WWKCN-PNDDK-CCRPK-LKCSK-LFKLC-NFSF, the C-terminus is amidated. The toxin is an amphipathic peptide consisting of a large hydrophobic patch which is surrounded by a ring of six polar lysine residues. These hydrophobic residues enable the toxin to carry an overall charge of +5. The toxin contains three intramolecular disulfide bonds that contribute to the formation of its inhibitor cystine knot (ICK).
Sources: en.wikipedia.org
Vericrustacea ("true crustaceans")—Branchiopoda, Copepoda, Malacostraca, Thecostraca. Multicrustacea ("numerous crustaceans")—Copepoda, Malacostraca, Thecostraca. Communostraca ("common shelled ones")—Malacostraca, Thecostraca. Miracrustacea ("surprising crustaceans")—Cephalocarida, Remipedia, Hexapoda. Xenocarida ("strange shrimp")—Cephalocarida, Remipedia. Of these proposed clades, only Multicrustacea was confirmed in later molecular studies.
=== Acute === Acute exposure to cadmium fumes may cause flu-like symptoms including chills, fever, and muscle ache sometimes referred to as "the cadmium blues." Symptoms may resolve after a week if there is no respiratory damage. More severe exposures can cause tracheobronchitis, pneumonitis, and pulmonary edema. Symptoms of inflammation may start hours after the exposure and include cough, dryness and irritation of the nose and throat, headache, dizziness, weakness, fever, chills, and chest pain.
The domain of automotive design has been traditionally characterized as male-dominated. As a result, there has been a lack of female automotive designers in the area of automotive safety compared to male automotive designers. This leads to oversights in automotive safety and ergonomics for female consumers, who make up 62% of all new cars sold in the USA. According to the Insurance Institute for Highway Safety (IIHS), women are less likely to get into a crash than men are. However, women are 17% more likely to die in a car crash and 73% more likely to sustain serious injuries from a crash when compared to men. In rear-end collisions, female drivers face a higher risk of whiplash injuries when compared to their male counterparts due to their lighter weight which causes them to be propelled forward more rapidly. To mitigate these problems, Consumer Reports states that regulators have called for a female crash dummy to be implemented in crash testing since 1980. When pregnant, women should continue to use seatbelts and airbags properly. A University of Michigan study found that "unrestrained or improperly restrained pregnant women are 5.7 times more likely to have an adverse fetal outcome than properly restrained pregnant women". If seatbelts are not long enough, extensions are available from the car manufacturer or an aftermarket supplier.
DNA polymerase III holoenzyme is the primary enzyme complex involved in prokaryotic DNA replication. It was discovered by Thomas Kornberg (son of Arthur Kornberg) and Malcolm Gefter in 1970. The complex has high processivity (i.e. the number of nucleotides added per binding event) and, specifically referring to the replication of the E. coli genome, works in conjunction with four other DNA polymerases (Pol I, Pol II, Pol IV, and Pol V). Being the primary holoenzyme involved in replication activity, the DNA Pol III holoenzyme also has proofreading capabilities that corrects replication mistakes by means of exonuclease activity reading 3'→5' and synthesizing 5'→3'. DNA Pol III is a component of the replisome, which is located at the replication fork. The replisome is composed of the following:
While it is thus possible to use uranium-233 as the fissile material of a nuclear weapon, speculation aside, there is scant publicly available information on this isotope actually having been weaponized:
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.